Table 4. Association between each indexes and EGFR and KRAS mutations status based on univariate analysis (p-values).
| Index | EGFR mutations | KRAS mutations | Association |
|---|---|---|---|
| Age | 0.70 | 0.79 | - |
| Gender | 0.047 | 0.06 | Female with EGFR mutations |
| Cancer staging | 0.54 | 0.68 | - |
| Smoking status (Current / former smoker vs never-smoker) | < 0.001 | 0.018 | Never-smoker with EGFR mutations, Current / former smoker with KRAS mutations |
| Pack Years | 0.002 | 0.21 | Low pack year smoking history (mostly never-smoker regarded as smoking history with 0 year) with EGFR mutations. |
| Maximum metabolic tumor diameter | 0.26 | 0.66 | - |
| SUVmax | 0.029 | 0.20 | Higher SUVmax with EGFR mutations |
| MTV | 0.16 | 0.09 | - |
| TLG | 0.26 | 0.06 | - |
| SD (> 1 cm) | 0.16 | 0.94 | - |
| 1/COV (> 1 cm) | 0.014 | 0.94 | Higher 1/COV with EGFR mutations |
| AUC (> 1 cm) | 0.036 | 0.88 | Higher AUC with EGFR mutations |
| SD (> 2 cm) | 0.07 | 0.70 | - |
| 1/COV (> 2 cm) | < 0.001 | 0.73 | Higher 1/COV with EGFR mutations |
| AUC (> 3 cm) | 0.012 | 0.45 | - |
| SD (> 3 cm) | 0.44 | 0.46 | - |
| 1/COV (> 3 cm) | 0.008 | 0.98 | Higher 1/COV with EGFR mutations |
| AUC (> 3 cm) | 0.07 | 0.49 | - |
MTV: metabolic tumor volume, TLG: total lesion glycolysis, SD: standard deviation, COV: coefficient of variation, AUC: area under the curve of the cumulative SUV-volume Histogram. Measurements within parentheses are indicated maximum metabolic tumor diameter